Publications and Presentations

From 2015-2021, the PIVOT pediatric preclinical testing consortium was called the NCI Pediatric Preclinical Testing Consortium (PPTC).

Publications

Publications: 2016-2023 (PubMed)

Presentations

2022

American Association of Cancer Research (AACR) Annual Meeting

Evaluation of the in vivo efficacy of the B7-H3 antibody-drug conjugate (ADC) DS-7300a: A report from the Pediatric Preclinical In Vivo Testing (PIVOT) program (pdf)

2021

American Society of Clinical Oncologists (ASCO) Annual Meeting

Testing of B7-H3 Targeting Antibody-Drug Conjugate (ADC) MGC018 in Models of Pediatric Solid Tumors by the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

American Association of Cancer Research (AACR) Annual Meeting

Evaluation of ROR1-targeted Antibody-Drug Conjugates (ADCs) Against ROR1 Expressing Pediatric Preclinical Models — A Report from the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

Pediatric Preclinical Testing Consortium Evaluation of the Dual SYK/FLT3 Inhibitor TAK-659 in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia (pdf)

Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models (pdf)

The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL) (pdf)

Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcoma and preclinical testing of BT1769, an MT1-MMP-targeted Bicycle® toxin conjugate, in osteosarcoma by the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

2020

American Association for Cancer Research-National Cancer Institute- European Organization for Resesarch and Treatment of Cancer Annual Meeting (AACR NCI EORTC)

Pediatric Preclinical Testing Consortium evaluation of the XPO1 inhibitor eltanexor against xenograft models of pediatric acute lymphoblastic leukemia (pdf)

Preclinical Evaluation of Trastuzumab Deruxtecan (T-DXd; DS-8201a), a HER2 Antibody Drug Conjugate, in Pediatric Solid Tumors by the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

2019

Connective Tissue Oncology Society (CTOS) Annual Meeting

Evaluation of ABBV-085, an antibody-drug conjugate targeting LRRC15, in Osteosarcoma by the Pediatric Preclinical Testing Consortium (pdf)

Evaluation of the TPO-R receptor agonist eltrombopag in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models (pdf)

American Society of Hematology (ASH) Annual Meeting

Pediatric Preclinical Testing Consortium Evaluation of the Novel Anti-Microtubule Drug E7130 in Xenograft Models of Early T-Cell Precursor Acute Lymphoblastic Leukemia (pdf)

AACR NCI EORTC

Initial Testing of m276-PBD CD276 Antibody Conjugate in Preclinical Models of Pediatric Cancers by the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia (pdf)

Integrative mass spectrometry and RNA-sequencing identifies DLK1 as a candidate immunotherapeutic target in neuroblastoma (pdf)

ASCO Annual Meeting

Initial in Vivo Testing of a Multi-kinase Inhibitor, Regorafenib, by the Pediatric Preclinical Testing Consortium (pdf)

AACR Annual Meeting

In vivo evaluation of the menininhibitor VTP-50469 against Ewing sarcoma preclinical models – A report from the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

Comparison of Thio-deoxyCytidine(TdCyd) and Aza-Thio-deoxyCytidine(Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts (pdf)

In vivo evaluation of the LSD1 inhibitor SP-2577 against Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma preclinical models – A report from the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

Pediatric Preclinical Testing Consortium evaluation of the anti-CD123 antibody-drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia (pdf)

Pediatric Preclinical Testing Consortium (PPTC) Testing of an OLIG2 Inhibitor CT-179 in Orthotopic PDX Models of Pediatric Glioblastomas (pdf)

Pediatric Preclinical Testing Consortium Re-evaluating Sample Sizes in Preclinical Testing of Patient-Derived Xenografts (pdf)

2018

ASH Annual Meeting

A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia by the Pediatric Preclinical Testing Consortium (pdf)

ASCO Annual Meeting

PPTC evaluation of the EZH2 Inhibitor Tazemetostat in Orthotopic PDX Models of Pediatric Brain Tumors (pdf)

AACR Annual Meeting

PPTC evaluation of eribulin osteosarcoma (OS) patient-derived xenograft (PDX) models (pdf)

PPTC evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia (pdf)

PPTC evaluation of a DLL3-targeted antibody drug conjugate, rovalpituzumab tesirine, in neuroblastoma (pdf)

2017

AACR NCI EORTC

PPTC Evaluation of OT-82 Against Patient-Derived Xenograft Models of High-Risk Acute Lymphoblastic Leukemia (pdf)

PPTC Evaluation of the CHK1 Inhibitor Prexasertib (pdf)

PPTC Evaluation of the AKR1C3-activated prodrug OBI-3424 exerts profound in vivo efficacy against preclinical models of T-cell acute lymphoblastic leukemia (T-ALL) (pdf)

PPTC Evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602 (pdf)

PPTC Evaluation of AZD1775 as a Single Agent and in Combination with Irinotecan (pdf)

PPTC Evaluation of 4′-thio-2′-deoxycytidine (TdCyd) and 5-aza-4′-thio-2′-deoxycytidine (Aza-TdCyd ) (pdf)